← Leaderboards
Eric H Kraut
Ohio State University
$13,897
Attributed
$13,897
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$13,897 · 2
By mechanism
M01$13,897 · 2
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Michael A Caligiuri$65,062,344
- Jessie L.-S. Au$10,705,345
- David P Carbone$20,647,321
- William E. Carson$27,905,247
- M Guillaume Wientjes$5,257,664
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsClinical ResearchClinical Trial Phase IHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyPaclitaxelPharmacokineticsCombination ChemotherapyHuman SubjectNeoplasm /CancerCombination Cancer TherapyDrug Adverse EffectDrug Screening /Evaluation
Grant awards (4)
A Phase I Study of Oxaliplatin in Combination with Paclitaxel$13,897
M01 · FY2004 · RR
PHASE I STUDY OF OXALIPLATIN IN COMBINATION WITH PACLITAXEL$0
M01 · FY2001 · RR
PHASE I STUDY OF OXALIPLATIN IN COMBINATION WITH PACLITAXEL$0
M01 · FY2000 · RR
PHASE I STUDY OF OXALIPLATIN IN COMBINATION WITH PACLITAXEL$0
M01 · FY2000 · RR